GILD

$GILD

Gilead Sciences, Inc.

Biopharmaceutical company focused on HIV, hepatitis, and oncology.

Healthcare
$166.53
-2.45 (-1.45%)
Day Range$164.80 - $169.16
Prev Close$168.98

GILD key facts as of November 14, 2026

Latest AI research report
GILD Stock: HIV Growth, Valuation and Risks (as of November 14, 2026)
StockAlpha report sentiment
Neutral (as of November 14, 2026)
Analyst consensus
Strong Buy (6 Strong Buy, 16 Buy, 5 Hold, 0 Sell, 1 Strong Sell) (as of November 1, 2026)
Analyst price target
$167.94 mean (range $126.00 to $196.00) (as of November 20, 2026)
Sector
Healthcare
Analyst Rating
Strong Buy
22 Buy / 5 Hold / 1 Sell
Price Target
$167.94
0.8% upside
Subscribers
1
Tracking this ticker
Latest Report

Analysis from Nov 14, 2026

NEUTRAL

GILD Stock: HIV Growth, Valuation and Risks

Gilead's HIV franchise and recent earnings beat provide constructive signals, while its share price is close to the supplied analyst consensus target. This report weighs the growth prospects against negative trailing GAAP metrics, drug-pricing risk and uncertainty around future earnings.

Nov 14, 2026

GILD FAQ

What is StockAlpha's latest view on GILD?

StockAlpha's latest AI research report on Gilead Sciences, Inc. (GILD), "GILD Stock: HIV Growth, Valuation and Risks", was published on November 14, 2026 and rates the overall sentiment as neutral. Gilead's HIV franchise and recent earnings beat provide constructive signals, while its share price is close to the supplied analyst consensus target. This report weighs the growth prospects against negative trailing GAAP metrics, drug-pricing risk and uncertainty around future earnings.

When was the GILD research last updated?

The most recent GILD report was published on November 14, 2026.

What do analysts expect for GILD?

As of November 1, 2026, the analyst consensus on GILD is Strong Buy (6 Strong Buy, 16 Buy, 5 Hold, 0 Sell, 1 Strong Sell). As of November 20, 2026, the analyst price target is $167.94 mean (range $126.00 to $196.00).

Is this GILD research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring